Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04492163 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM | PHASE2 | COMPLETED | 25 | — | — | Jul 14, 2020 | Jun 20, 2023 | Aug 16, 2024 | 1 | Czechia |
PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria.
| Arm | Type | Description |
|---|---|---|
| Experimental: TTFields | EXPERIMENTAL | Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays. |
| Name | Type | Description |
|---|---|---|
| TTFields | DEVICE | TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine. Other Names: • TTFields |
Inclusion Criteria: 1. Histologically confirmed diagnosis of GBM according to WHO classification criteria. 2. Age ≥ 18 years 3. Not a candidate for further radiotherapy or additional resection of residual tumor. 4. Patients with first or second radiological disease progression per RANO criteria doc...